Latest Secondary Hyperparathyroidism (SHPT) News
The researchers found that patients of high-volume surgeons had a lower rate of vocal cord paralysis compared to patients of low-volume surgeons.
At 18 months, PTH levels were within target for 67% and 68% of participants who initiated etelcalcetide at 2.5 mg and 5 mg, respectively.
Nearly twice as many patients achieved the target phosphorus range after a year of taking the phosphate binder, regardless of iPTH level.
Cinacalcet treatment may serve as a bridge to parathyroidectomy or as an alternative, researchers say.
Replacing foods containing phosphorus-based additives with similar foods not containing these additives can control hyperphospatemia without interfering with nutritional status.
Researchers using spectral computed tomography found that calcium concentration increased in cortical bone and decreased in cancellous bone.
Bone expression of sclerostin and parathyroid hormone receptor-1 increased in earlier stages of CKD, whereas FGF-23 and phosphorylated b-catenin showed increased expression in later stages.
Alkaline phosphatase was more strongly linked to mortality compared with other biomarkers of chronic kidney disease-mineral and bone disorder.
Study suggests the lowest dose of vitamin D3 supplements needed to suppress parathyroid hormone in overweight and obese adults is 1000 IU daily.
In a study, similar proportions of patients taking a low dose and standard dose of cinacalcet had a greater than 30% reduction in iPTH levels at 16 weeks.
Adipose tissue may be more important than vitamin D intake, new study suggests.
Clinicians should be aware of these uncommon radiograph findings.
Etelcalcetide is the first new approved treatment for the condition in 12 years.
Priority should be to achieve target calcium levels or simultaneously achieving both phosphorus and iPTH levels, researchers say.
Dialysis facilities with the least control of PTH, Ca, and P had the greatest risks.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)